ARCH Venture Management, LLC
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), ARCH Venture Management, LLC reported 9 stock positions worth $492.4 million. Its top holding was Rapport Therapeutics (RAPP) at 22.5% of the portfolio, followed by Beam Therapeutics (BEAM, 22.4%) and Maze Therapeutics (MAZE, 21.7%). Compared with Q2 2025, it sold out of 2 and added to 1. The biggest buy was Lyell Immunopharma (LYEL, shares +52%) and the biggest sale an exit from Verve Therapeutics (VERV).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $492.4M (Q3 2025)
- SEC Filing
- 0001012975-25-000787 ↗ filed Nov 14, 2025
Holdings Value
Holdings 9 stocks · $492.4M
| RAPP Rapport Therapeutics Inc. | 22.49% | 3,728,738 | $110.7M | No change |
| BEAM Beam Therapeutics Inc. | 22.38% | 4,540,132 | $110.2M | No change |
| MAZE Maze Therapeutics Inc. | 21.70% | 4,120,053 | $106.8M | No change |
| VIR Vir Biotechnology Inc. | 14.98% | 12,916,663 | $73.8M | No change |
| LYEL Lyell Immunopharma Inc. | 9.10% | 2,759,072 | $44.8M | Add +51.5% |
| ERAS Erasca Inc. | 4.89% | 11,055,554 | $24.1M | No change |
| GOSS Gossamer Bio Inc. | 4.30% | 8,055,916 | $21.2M | No change |
| QTTB Q32 Bio Inc. | 0.13% | 320,482 | $635K | No change |
| CERO Cero Therapeutics Holdings I | 0.02% | 22,389 | $114K | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
| LYEL Lyell Immunopharma Inc. | Add +51.5% | 9.10% | +3.71 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |